CV Therapeutics has announced it will file a new drug application to the FDA for its regadenoson agent in mid-2007 following positive results from a late-stage trial, the Associated Press reported Monday.

Regadenoson is used in myocardial perfusion imaging studies, or studies on coronary artery disease. CV Therapeutics said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies.

AngioDynamics, Inc. has announced FDA 510(k) clearance for Oncobionic, Inc. to market Irreversible Electroporation (IRE) — a technology approved for the surgical ablation of soft tissue, including cardiac and smooth muscle.

AngioDynamic’s acquisition of Oncobionic for a total of $25 million will be completed following successful human use of its IRE technology, testing that is expected to begin mid-year 2007.

Possis Medical, Inc. has received clearance from the FDA to market its AngioJet Xpeedior catheter to remove blood clots (thrombus) from upper- and lower-extremity peripheral veins. Used with the company’s AngioJet System, Xpeedior is the only device cleared for thrombectomy in peripheral veins.

The Third International Conference on Cell Therapy for Cardiovascular Diseases will convene Jan 17 to 19, at The New York Academy of Medicine in New York, NY. The three-day program is dedicated to the evolving field of cell-based therapies for cardiac repair and regeneration.

GE Healthcare has launched its new LightSpeed VCT XT, the industry’s first CT scanner that maintains outstanding image quality while reducing a patient’s radiation exposure by up to 70 percent for diagnostic cardiac scans. The company unveiled the technology this week during the annual meeting of the Radiological Society of North America in Chicago.